Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AB521 |
Synonyms | |
Therapy Description |
AB521 selectively inhibits HIF-2alpha, potentially resulting in downregulation of HIF-2alpha target genes and antitumor activity (Ann Oncol 33 (2022): S21). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AB521 | AB-521|AB 521 | HIF2A Inhibitor 6 | AB521 selectively inhibits HIF-2alpha, potentially resulting in downregulation of HIF-2alpha target genes and antitumor activity (Ann Oncol 33 (2022): S21). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05536141 | Phase I | AB521 | A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors (ARC-20) | Recruiting | USA | AUS | 1 |